Q-omics provides the consensus-scored DEFB129 profile across patient tissues and cancer cell-line models. DEFB129 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, DEFB129 is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, DEFB129 RNA expression shows 5,850 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, PRAD, and STAD as cancer lineages where DEFB129 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DEFB129 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DEFB129 survival associations across molecular data types. DEFB129 RNA expression shows survival associations in the most cancer types (6), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DEFB129 RNA expression–survival associations across cancer types. High DEFB129 expression shows unfavorable associations in THCA, BLCA, SCLC, DLBC and LGG, but favorable associations in KICH. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify THCA as the clearest survival context for DEFB129 RNA expression.
This table summarizes DEFB129 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DEFB129. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DEFB129 shows lower tumor expression in PRAD and higher tumor expression in THCA. The PRAD box plot shows higher DEFB129 RNA expression in normal versus tumor tissue (log2 FC = −0.515, t-test p = .013).
This table shows molecular features associated with DEFB129 in patient tissues and cancer cell lines. In patient samples, DEFB129 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, DEFB129 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_NSCLC_LUAD.
